Nasrien Ezzeldin Ibrahim, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 56 | 2024 | 10900 | 4.760 |
Why?
|
Natriuretic Peptide, Brain | 15 | 2023 | 1573 | 3.250 |
Why?
|
Stroke Volume | 27 | 2024 | 5007 | 2.570 |
Why?
|
Tetrazoles | 5 | 2020 | 835 | 1.490 |
Why?
|
Peptide Fragments | 11 | 2023 | 5097 | 1.270 |
Why?
|
Ventricular Dysfunction, Left | 4 | 2021 | 2073 | 1.140 |
Why?
|
Adrenergic beta-Antagonists | 4 | 2019 | 1240 | 1.040 |
Why?
|
Biphenyl Compounds | 7 | 2020 | 913 | 1.040 |
Why?
|
Angiotensin Receptor Antagonists | 7 | 2020 | 924 | 0.990 |
Why?
|
Ventricular Remodeling | 4 | 2020 | 1224 | 0.910 |
Why?
|
Coronary Angiography | 7 | 2020 | 4577 | 0.870 |
Why?
|
Shock, Cardiogenic | 4 | 2022 | 688 | 0.870 |
Why?
|
Natriuretic Peptides | 3 | 2021 | 150 | 0.860 |
Why?
|
Cardiovascular Agents | 2 | 2020 | 850 | 0.840 |
Why?
|
Ventricular Function, Left | 7 | 2024 | 3670 | 0.800 |
Why?
|
Atrial Appendage | 1 | 2023 | 283 | 0.690 |
Why?
|
Baroreflex | 1 | 2020 | 146 | 0.690 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2020 | 216 | 0.670 |
Why?
|
Neprilysin | 3 | 2020 | 439 | 0.630 |
Why?
|
Drug Combinations | 8 | 2020 | 1959 | 0.620 |
Why?
|
Coronary Stenosis | 4 | 2020 | 834 | 0.610 |
Why?
|
Endothelin-1 | 2 | 2018 | 314 | 0.610 |
Why?
|
Social Justice | 1 | 2022 | 456 | 0.600 |
Why?
|
Heart Rate | 2 | 2019 | 4091 | 0.570 |
Why?
|
Coronary Artery Disease | 8 | 2023 | 6487 | 0.560 |
Why?
|
Angiography | 3 | 2018 | 1639 | 0.540 |
Why?
|
Renin-Angiotensin System | 2 | 2018 | 759 | 0.530 |
Why?
|
Catheterization | 2 | 2018 | 1470 | 0.530 |
Why?
|
Healthcare Disparities | 4 | 2023 | 3158 | 0.530 |
Why?
|
Catheters | 1 | 2018 | 425 | 0.520 |
Why?
|
Atrial Natriuretic Factor | 3 | 2021 | 393 | 0.520 |
Why?
|
Risk Assessment | 12 | 2020 | 23338 | 0.510 |
Why?
|
Transcutaneous Electric Nerve Stimulation | 1 | 2017 | 161 | 0.500 |
Why?
|
Proteomics | 4 | 2020 | 3638 | 0.470 |
Why?
|
Dyspnea | 2 | 2021 | 1303 | 0.450 |
Why?
|
Defibrillators, Implantable | 2 | 2022 | 1440 | 0.450 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1071 | 0.420 |
Why?
|
Diabetic Cardiomyopathies | 2 | 2024 | 96 | 0.410 |
Why?
|
Humans | 82 | 2024 | 744343 | 0.400 |
Why?
|
Disease Management | 2 | 2021 | 2459 | 0.380 |
Why?
|
Cardiovascular Diseases | 8 | 2022 | 15165 | 0.380 |
Why?
|
Heart Neoplasms | 1 | 2014 | 374 | 0.380 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2017 | 531 | 0.380 |
Why?
|
Acute Kidney Injury | 3 | 2020 | 1972 | 0.370 |
Why?
|
Peripheral Arterial Disease | 2 | 2018 | 1188 | 0.370 |
Why?
|
Renal Insufficiency | 1 | 2016 | 804 | 0.370 |
Why?
|
Pericardium | 1 | 2014 | 667 | 0.360 |
Why?
|
Prognosis | 13 | 2023 | 29063 | 0.350 |
Why?
|
Health Status Disparities | 1 | 2020 | 1797 | 0.330 |
Why?
|
Salaries and Fringe Benefits | 2 | 2021 | 264 | 0.320 |
Why?
|
Cardiology | 5 | 2024 | 1668 | 0.320 |
Why?
|
Heart-Assist Devices | 4 | 2022 | 1194 | 0.310 |
Why?
|
Clinical Trials as Topic | 3 | 2021 | 7913 | 0.300 |
Why?
|
Heart Transplantation | 4 | 2021 | 3110 | 0.290 |
Why?
|
Prospective Studies | 16 | 2021 | 53288 | 0.290 |
Why?
|
Diuretics | 3 | 2020 | 592 | 0.290 |
Why?
|
Guideline Adherence | 1 | 2017 | 2266 | 0.280 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2019 | 1518 | 0.280 |
Why?
|
Troponin | 2 | 2021 | 524 | 0.280 |
Why?
|
Troponin I | 3 | 2020 | 619 | 0.280 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4456 | 0.270 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3610 | 0.270 |
Why?
|
Predictive Value of Tests | 9 | 2020 | 15076 | 0.270 |
Why?
|
Artificial Intelligence | 1 | 2019 | 2214 | 0.260 |
Why?
|
Contrast Media | 1 | 2019 | 5300 | 0.260 |
Why?
|
Atrial Fibrillation | 1 | 2023 | 5034 | 0.250 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 2208 | 0.250 |
Why?
|
Registries | 5 | 2023 | 8089 | 0.240 |
Why?
|
Aged | 24 | 2024 | 163280 | 0.240 |
Why?
|
ROC Curve | 4 | 2021 | 3527 | 0.230 |
Why?
|
Electrocardiography | 1 | 2017 | 6442 | 0.230 |
Why?
|
Male | 34 | 2024 | 350118 | 0.220 |
Why?
|
Middle Aged | 26 | 2022 | 213383 | 0.220 |
Why?
|
Female | 35 | 2024 | 380194 | 0.220 |
Why?
|
Time Factors | 9 | 2023 | 40075 | 0.220 |
Why?
|
Treatment Outcome | 10 | 2022 | 63114 | 0.200 |
Why?
|
Research Design | 1 | 2016 | 5987 | 0.190 |
Why?
|
Myocardial Infarction | 5 | 2022 | 11727 | 0.180 |
Why?
|
Endorphins | 1 | 2020 | 75 | 0.180 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 2020 | 90 | 0.180 |
Why?
|
Glomerular Filtration Rate | 2 | 2018 | 2170 | 0.180 |
Why?
|
Follow-Up Studies | 8 | 2020 | 39050 | 0.180 |
Why?
|
Pharmacological Phenomena | 1 | 2019 | 11 | 0.170 |
Why?
|
Hyperlipoproteinemias | 1 | 2019 | 20 | 0.170 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2020 | 336 | 0.170 |
Why?
|
Recovery of Function | 2 | 2020 | 2925 | 0.160 |
Why?
|
Risk Factors | 11 | 2020 | 72290 | 0.160 |
Why?
|
United States | 12 | 2024 | 69872 | 0.150 |
Why?
|
Cardiotonic Agents | 1 | 2020 | 535 | 0.150 |
Why?
|
Apolipoproteins | 1 | 2019 | 317 | 0.140 |
Why?
|
Glucosides | 1 | 2020 | 451 | 0.140 |
Why?
|
Health Promotion | 2 | 2019 | 2205 | 0.140 |
Why?
|
Adenocarcinoma | 1 | 2014 | 6364 | 0.140 |
Why?
|
Cardiovascular System | 1 | 2024 | 832 | 0.140 |
Why?
|
Angiotensins | 1 | 2017 | 151 | 0.140 |
Why?
|
Evaluation Studies as Topic | 1 | 2018 | 1681 | 0.140 |
Why?
|
Reimbursement Mechanisms | 1 | 2021 | 670 | 0.130 |
Why?
|
Health Services Accessibility | 2 | 2023 | 5137 | 0.130 |
Why?
|
Diabetes Complications | 1 | 2022 | 1359 | 0.130 |
Why?
|
Autonomic Nervous System | 1 | 2020 | 671 | 0.130 |
Why?
|
Echocardiography | 3 | 2020 | 5102 | 0.130 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 135 | 0.130 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2017 | 365 | 0.130 |
Why?
|
Incidence | 5 | 2023 | 20947 | 0.130 |
Why?
|
Dyslipidemias | 1 | 2022 | 849 | 0.130 |
Why?
|
Chest Pain | 1 | 2022 | 1114 | 0.130 |
Why?
|
Cachexia | 1 | 2016 | 204 | 0.120 |
Why?
|
Catheterization, Peripheral | 1 | 2018 | 345 | 0.120 |
Why?
|
Benzhydryl Compounds | 1 | 2020 | 845 | 0.120 |
Why?
|
Patient Care Management | 1 | 2017 | 306 | 0.120 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2024 | 11725 | 0.120 |
Why?
|
Kidney Function Tests | 1 | 2016 | 684 | 0.120 |
Why?
|
Disease Progression | 4 | 2018 | 13284 | 0.120 |
Why?
|
Myocarditis | 1 | 2021 | 771 | 0.110 |
Why?
|
Physicians, Women | 1 | 2019 | 486 | 0.110 |
Why?
|
Sex Factors | 4 | 2021 | 10397 | 0.110 |
Why?
|
Practice Guidelines as Topic | 3 | 2019 | 7279 | 0.110 |
Why?
|
Tissue Donors | 2 | 2021 | 2240 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2016 | 601 | 0.110 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15540 | 0.110 |
Why?
|
Creatinine | 1 | 2019 | 1919 | 0.110 |
Why?
|
Chronic Disease | 3 | 2017 | 9146 | 0.110 |
Why?
|
Blood Proteins | 1 | 2018 | 1124 | 0.110 |
Why?
|
Drug Monitoring | 1 | 2019 | 956 | 0.110 |
Why?
|
Consensus | 4 | 2024 | 2959 | 0.100 |
Why?
|
Diffusion of Innovation | 1 | 2017 | 725 | 0.100 |
Why?
|
Myocardial Ischemia | 1 | 2022 | 2148 | 0.100 |
Why?
|
Patient Participation | 1 | 2021 | 1457 | 0.100 |
Why?
|
Analysis of Variance | 2 | 2019 | 6365 | 0.100 |
Why?
|
Hepatitis C, Chronic | 1 | 2019 | 1031 | 0.100 |
Why?
|
Prevalence | 4 | 2023 | 15226 | 0.100 |
Why?
|
Retrospective Studies | 6 | 2023 | 77449 | 0.090 |
Why?
|
Health Status | 2 | 2020 | 4034 | 0.090 |
Why?
|
Quality of Life | 2 | 2022 | 12804 | 0.090 |
Why?
|
Lung Neoplasms | 1 | 2014 | 13102 | 0.090 |
Why?
|
Stroke | 2 | 2022 | 9981 | 0.090 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12354 | 0.090 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2020 | 1354 | 0.090 |
Why?
|
Patient Selection | 2 | 2022 | 4215 | 0.080 |
Why?
|
Heart | 2 | 2019 | 4467 | 0.080 |
Why?
|
Cross-Sectional Studies | 5 | 2021 | 25043 | 0.080 |
Why?
|
Cause of Death | 1 | 2019 | 3584 | 0.080 |
Why?
|
Outpatients | 1 | 2016 | 1486 | 0.080 |
Why?
|
Quality Improvement | 1 | 2023 | 3749 | 0.080 |
Why?
|
Massachusetts | 2 | 2018 | 8663 | 0.080 |
Why?
|
Cohort Studies | 4 | 2019 | 40561 | 0.070 |
Why?
|
Oxidative Stress | 1 | 2018 | 3086 | 0.070 |
Why?
|
Survival Analysis | 2 | 2019 | 10252 | 0.070 |
Why?
|
Antiviral Agents | 1 | 2019 | 2987 | 0.070 |
Why?
|
Medicare | 2 | 2021 | 6566 | 0.070 |
Why?
|
Adult | 7 | 2023 | 214055 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2019 | 57776 | 0.060 |
Why?
|
Ambulatory Care | 1 | 2016 | 2708 | 0.060 |
Why?
|
MicroRNAs | 1 | 2021 | 3752 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10943 | 0.060 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3537 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2020 | 13989 | 0.060 |
Why?
|
Hospital Mortality | 3 | 2023 | 5317 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8388 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5751 | 0.060 |
Why?
|
Aldehyde Reductase | 1 | 2022 | 65 | 0.060 |
Why?
|
Hypertension | 1 | 2022 | 8480 | 0.050 |
Why?
|
Apoptosis | 1 | 2018 | 9727 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2019 | 4468 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2018 | 19905 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2022 | 5078 | 0.050 |
Why?
|
Hospitalization | 2 | 2023 | 10262 | 0.050 |
Why?
|
Censuses | 1 | 2022 | 200 | 0.050 |
Why?
|
Telemedicine | 1 | 2018 | 2872 | 0.050 |
Why?
|
Habits | 1 | 2021 | 139 | 0.050 |
Why?
|
Telephone | 1 | 2022 | 617 | 0.040 |
Why?
|
American Heart Association | 1 | 2023 | 1056 | 0.040 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2024 | 859 | 0.040 |
Why?
|
Kidney Tubules | 1 | 2020 | 488 | 0.040 |
Why?
|
Exercise Tolerance | 1 | 2022 | 770 | 0.040 |
Why?
|
Quinoxalines | 1 | 2019 | 290 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2019 | 342 | 0.040 |
Why?
|
Pilot Projects | 2 | 2021 | 8324 | 0.040 |
Why?
|
Principal Component Analysis | 1 | 2020 | 940 | 0.040 |
Why?
|
Animals | 4 | 2022 | 168757 | 0.040 |
Why?
|
Morbidity | 1 | 2022 | 1769 | 0.040 |
Why?
|
Advisory Committees | 1 | 2021 | 775 | 0.040 |
Why?
|
Podocytes | 1 | 2020 | 396 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2022 | 1660 | 0.030 |
Why?
|
Waiting Lists | 1 | 2019 | 692 | 0.030 |
Why?
|
Lipoproteins, HDL | 1 | 2019 | 638 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3339 | 0.030 |
Why?
|
Th17 Cells | 1 | 2021 | 766 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2297 | 0.030 |
Why?
|
Adiponectin | 1 | 2020 | 1100 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2019 | 850 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2019 | 2971 | 0.030 |
Why?
|
Standard of Care | 1 | 2016 | 564 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2021 | 6386 | 0.030 |
Why?
|
Primary Prevention | 1 | 2019 | 1167 | 0.030 |
Why?
|
Hepacivirus | 1 | 2019 | 1379 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2019 | 2203 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2021 | 6171 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2021 | 18029 | 0.020 |
Why?
|
Ischemic Attack, Transient | 1 | 2016 | 935 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2016 | 921 | 0.020 |
Why?
|
Sulfonamides | 1 | 2019 | 1938 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 2133 | 0.020 |
Why?
|
Hemodynamics | 1 | 2019 | 4199 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3778 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2022 | 12026 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9734 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9849 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3507 | 0.020 |
Why?
|
Critical Illness | 1 | 2020 | 2670 | 0.020 |
Why?
|
Databases, Factual | 1 | 2021 | 7729 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3679 | 0.020 |
Why?
|
Medicaid | 1 | 2019 | 2736 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2021 | 14557 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12959 | 0.020 |
Why?
|
Acute Disease | 1 | 2016 | 7149 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14722 | 0.020 |
Why?
|
Weight Loss | 1 | 2016 | 2622 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2018 | 3528 | 0.020 |
Why?
|
Boston | 1 | 2018 | 9313 | 0.020 |
Why?
|
Models, Biological | 1 | 2020 | 9583 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10180 | 0.010 |
Why?
|
Mice | 2 | 2021 | 81183 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9274 | 0.010 |
Why?
|
Survival Rate | 1 | 2017 | 12788 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2022 | 7659 | 0.010 |
Why?
|
Obesity | 1 | 2022 | 12745 | 0.010 |
Why?
|
Body Mass Index | 1 | 2016 | 12720 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2020 | 15295 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 56430 | 0.010 |
Why?
|